205 results about "Cerebral ischaemia" patented technology

The invention discloses an intelligent decision-making method for a cerebral ischemia drug administration time window, and relates to the technical field of intelligent decision-making. The method comprises the following steps: S1, acquiring parameters, and setting a cerebral ischemia drug configuration scheme; s2, extracting a medicine characteristic parameter set and a medicine taking influence parameter set; s3, calculating a drug combination risk parameter set; s4, performing hierarchical classification processing on the drug combination risk parameter set, and performing drug correlation analysis; s5, performing weighted fusion on a correlation analysis result in combination with a drug influence attenuation rule, generating a drug administration time window evaluation parameter, and adding a label; and S6, according to the parameters, the labels and the configuration scheme, generating a cerebral ischemia drug administration time window intelligent decision scheme, and performing storage and backup. According to the method, by combining directional extraction of the drug characteristic parameter set and the drug taking influence parameter set with Pearson correlation algorithm screening, decision errors caused by data deviation are avoided.

The invention relates to an astragaloside-loaded astragalus membranaceus exosome which is prepared by the following steps: crushing astragalus membranaceus, and filtering to obtain juice; performing multi-step differential centrifugation to obtain supernate; carrying out ultrafiltration and centrifugation, and collecting the precipitate; adding to the upper layer of a sucrose stepped gradient solution, centrifuging, and collecting part of strips; after dilution, centrifuging, discarding the supernatant, precipitating, and removing cane sugar to obtain the astragalus membranaceus exosome; the radix astragali exosome loaded with the astragaloside is obtained by mixing the radix astragali exosome with the astragaloside and carrying out ultrasonic treatment or co-incubation, and can be used for preparing medicines for specifically inhibiting cGAS / STING pathway excessive activation in cerebral ischemia reperfusion injury and downstream NLRP3 inflammasome mediated pyroptosis and preparing medicines for protecting and repairing mitochondria in the cerebral ischemia reperfusion injury. The homologous astragalus membranaceus exosome is used as a natural carrier, the blood-brain barrier is effectively overcome, and the enrichment concentration and bioavailability of astragaloside in a cerebral ischemia area are remarkably improved.

The invention relates to a bionic nano CO generator as well as preparation and application thereof, belongs to the technical field of medicines, and solves the problem that a CO delivery system which can synergistically promote neuroprotection and neurogenesis and has brain targeting and controlled release capabilities is urgently required to be developed at present. According to the technical scheme, the bionic nano CO generator comprises a drug-loaded particle inner core and a covering film, the drug-loaded particle inner core comprises hollow mesoporous CeO2 nano particles and MnCO loaded on the hollow mesoporous CeO2 nano particles, and the covering film is a macrophage membrane and wraps the drug-loaded particle inner core. The compound is used for apoplexy treatment administration by integrating neuroprotection and enhancing innovative dual channels of endogenous nerve growth, and is expected to significantly reduce brain injury after cerebral apoplexy and restore neurological functions so as to relieve the worry about high death rate and long-term disability after cerebral ischemia-reperfusion injury.

The invention discloses an image processing and simulation analysis method for a carotid artery image, which comprises the following steps: firstly, acquiring a CTA image, observing and selecting, then importing the CTA image, adjusting the image contrast, generating a three-dimensional blood vessel model, extracting a carotid artery focus, and carrying out overall and local surface optimization processing on the model. The method comprises the steps that firstly, a model is built, then local surface cutting naming and grid division are conducted on the model, finally parameters are set, CFD hemodynamic simulation is conducted, a simulation result is subjected to visualization processing, and preoperative and postoperative data are compared and analyzed. According to the method, multi-modal imaging data of brain CT perfusion imaging, brain CT angiography and the like of a patient suffering from carotid artery stenosis can be collected to be used for reconstructing a three-dimensional model of the carotid artery stenosis, the carotid artery hemodynamic characteristics of the patient and the individual characteristics of the patient are analyzed in an auxiliary mode based on computational fluid mechanics, operation mode selection is optimized, and the three-dimensional model of the carotid artery stenosis is reconstructed. Cerebral ischemia reperfusion injury is avoided, clinical prognosis of a patient is improved, and life quality of the patient is improved.

The invention provides an application of combination of indobufen and butylphthalide in preparation of a drug for preventing and / or treating cerebrovascular diseases, indobufen and butylphthalide are combined for use, have a synergistic effect, remarkably improve the treatment effect, can be used for preparing the drug for preventing, secondarily preventing or treating the cerebrovascular diseases, and has a wide application prospect. The medicine is especially suitable for treating cerebral apoplexy and transient ischemic attack, and can be used for prophylactically improving cerebral infarction caused by cerebral arterial thrombosis.

The invention relates to the technical field of biological medicine, in particular to 7-dehydrocholesterol liposome and application thereof. According to the invention, a biological membrane modified liposome is constructed, and the biological membrane modified liposome comprises an ROS responsive liposome, a neutrophile granulocyte membrane and a renal tubular epithelial cell membrane; the biofilm modified liposome has an active oxygen species (ROS) responsive release function and a dual targeting capability, has the advantages of an integrated drug effect carrier, ROS triggered release, dual bionic targeting, strong target cell uptake and multi-mechanism ferroptosis resistance, and can be used for preparing the biofilm modified liposome. The compound can be used for treating ferroptosis related diseases such as acute kidney injury, myocardial ischemia-reperfusion injury and cerebral ischemia-reperfusion injury, and has wide clinical popularization value.

The utility model belongs to the field of experimental devices, and relates to a 360-degree rotating device capable of continuously transmitting bilateral electroencephalogram and myoelectricity of a freely moving rat for a long time. The device is mainly composed of a small conductive slip ring, a slip ring stator end wire protection cover, a slip ring rotor end wire fixing clamping box, a double-row pin header and an acrylic fixing shelf. A wire at a stator end of the small conductive slip ring is welded with the two double-row contact pins and is a bilateral electroencephalogram and electromyographic signal transmitting end; a wire at the rotor end of the slip ring is welded with the double-row pin header and is a bilateral electroencephalogram and electromyographic signal input end; and the main body of the slip ring is fixed on the acrylic shelf through a flange. The novel experimental device is small and light, stable in signal transmission, low in cost and capable of respectively recording electroencephalograms of brains on the left side and the right side of the rat for a long time and providing powerful help for basic experimental researches such as evaluation of brain function states and prognosis of injuries such as cerebral ischemia, evaluation of treatment effects and screening of new intervention measures.

This invention discloses a class of aminosalicylic acid derivative compounds, their pharmaceutical compositions, and uses. The aminosalicylic acid derivatives of this invention can significantly improve ischemic symptoms in rats with a cerebral ischemia-reperfusion model, and these compounds have broad application prospects in the preparation of drugs for the prevention and treatment of stroke.

The present invention recognizes that there is a need for the prophylaxis or treatment of Stroke Related Disorders, which includes but is not limited to stroke, ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and related cardiovascular diseases, or combinations thereof, or combinations thereof. A first aspect of the present invention generally relates to methods of prophylaxis or treatment of Stroke Related Disorders using various pharmaceutical compositions. A second aspect of the present invention generally relates to pharmaceutical compositions used for the prophylaxis or treatment of Stroke Related Disorders.

A traditional Chinese medicine formula for treating blood vessel clogging belongs to the field of traditional Chinese medicine formulas, and comprises the following main raw materials: 29-31 parts of black pearl, 11-13 parts of codonopsis pilosula, 7-9 parts of saffron crocus, 8-10 parts of angelica sinensis, 190-210 parts of leek, 9-11 parts of pseudo-ginseng, 37-43 parts of hawthorn, 95-105 parts of astragalus membranaceus, 18-22 parts of kudzu vine root, 8-10 parts of peach kernel, 8-10 parts of prepared rehmannia root, 9-11 parts of radix rehmanniae, 11-13 parts of white paeony root, 3 parts of red ginseng, 9-11 parts of radix ophiopogonis, 14-16 parts of spina date seed, 11-13 parts of Chinese yam, 14-15 parts of schisandra chinensis, 9-11 parts of polygonum multiflorum, 7-9 parts of cinnamon, 18-21 , 13-15 parts of anise and 12-14 parts of rhizoma polygonati. The traditional Chinese medicine composition has an obvious improvement effect on coronary artery insufficiency, myocardial ischemia, mitral valve, tricuspid valve, aortic valve regurgitation, chronic heart failure, patients needing operation bypass stenting, angina pectoris, myocardial infarction sequelae, cerebral ischemia, cerebrovascular sequelae and other symptoms caused by cardiac insufficiency, the dosage is small, the effect is fast, the cure rate is high, relapse is not prone to occurring, and the traditional Chinese medicine composition is suitable for clinical application. The effects of tonifying qi and activating blood, dredging channels and relieving pain, eliminating phlegm and removing blood stasis, tonifying heart and soothing nerves and the like can be achieved.

The invention discloses application of miR-6340 in preparation of a medicine for treating cerebral ischemia. Metabolism of GM1 in MCAO / R rats and metabolism of ganglioside GM1 in microglial cells after OGD / R can be inhibited by down-regulating expression of Glb1. It is found that upstream miRNA (miR-6340) of a Glb1 protein coding gene and mir-6340 / Glb1 promote the autophagy process of microglial cells through metabolism of GM1. According to the application, a new view angle is provided for the neuroprotective effect of GM1 on OGD / R induction by reducing autophagy.

The invention provides a traditional Chinese medicine preparation for cerebral arterial thrombosis, and belongs to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is prepared from gentiana macrophylla, divaricate saposhnikovia root, mulberry leaf, radix scrophulariae, ruddle, bulbus fritillariae cirrhosae, bamboo juice, selfheal, poria with hostwood and szechwan chinaberry fruit, and the whole formula has the effects of calming liver and suppressing yang, calming endogenous wind and relieving convulsion, eliminating phlegm and inducing resuscitation. The traditional Chinese medicine preparation has a remarkable improvement effect on the neurological function of a cerebral ischemia reperfusion injury model rat, can effectively reduce the water content of the brain tissue of the rat and the cerebral infarction volume, remarkably improves the levels of GSH and SOD in the brain tissue of the rat, reduces the MDA level, and has the effect of improving oxidative stress induced by cerebral ischemia reperfusion. The traditional Chinese medicine preparation can effectively relieve neurological function loss of a patient suffering from cerebral arterial thrombosis, help to recover life functions of the patient and relieve clinical symptoms of the patient, is definite and remarkable in curative effect and can be used as a new medicine for treating cerebral arterial thrombosis.

The invention discloses an aromatic alkylamine ferroptosis inhibitor based on a butylphthalide structure and a preparation method and application thereof. The chemical structural formula of the ferroptosis inhibitor is shown as a formula 1 or a formula 2. The ferroptosis inhibitor can inhibit ferroptosis caused by a ferroptosis inducer and can reduce the level of active oxygen in cells. Nerve injury caused by cerebral ischemia reperfusion can be relieved, and symptoms of neurological diseases such as Alzheimer's disease and Parkinson's disease can be relieved; compared with a ferroptosis inhibitor Ferrostatin-1, the aryl alkyl amine compound disclosed by the invention has better metabolic stability and is suitable for in-vivo drug effect evaluation. Therefore, the novel aryl alkyl amine compound provided by the invention has a very good application value in treatment of neurological diseases related to ferroptosis.

The application discloses an indigo red derivative, a preparation method of the indigo red derivative, and application of the indigo red derivative in preparation of an anti-cerebral ischemia neuroprotective drug or a drug component. The indigo red derivative has good anti-cerebral ischemia neuroprotective activity, can overcome defects of existing active ingredients, such as easy bleeding, difficulty in penetrating a blood-brain barrier, poor oral bioavailability, low selectivity, and high neurobehavioral toxicity, and can be used as a cerebral neuroprotective active ingredient for treatment of ischemic cerebral stroke. According to an animal experiment of cerebral neuroprotective activity screening, it can be seen that after the compound is given preventively, the survival time of acute cerebral ischemia mice can be obviously prolonged, and the compound has good anti-cerebral ischemia neuroprotective effect.

The invention relates to the technical field of medicines, in particular to application of DP-b99 and a derivative thereof in preparation of a medicine for treating cerebral ischemia mechanical thrombus extraction reperfusion injury. On the basis of mechanical thrombus extraction and reperfusion of cerebral ischemia, DP-b99 is combined to reduce mechanical thrombus extraction and reperfusion injury of cerebral arterial thrombosis, so that the inflammation level of brain tissues can be reduced, the volume of cerebral infarction can be reduced, the injury of the brain tissues can be effectively reduced, and the treatment effect is remarkable.

The invention relates to the technical field of medicines, in particular to application of benzbromarone in preparation of antithrombotic drugs. The research finds that benzbromarone clinically used for treating hyperuricemia can be combined with HSP47 on platelets to inhibit the interaction between the HSP47 and collagen so as to reduce platelet activation and thrombosis, which prompts that benzbromarone is an HSP47 inhibitor with an anti-platelet effect; benzbromarone has the effects of inhibiting mouse common carotid artery thrombosis and relieving cerebral ischemia reperfusion injury. Experiments finally confirm that benzbromarone can inhibit formation of common carotid artery thrombosis, does not affect the blood coagulation function, is low in cytotoxicity, has the drug effect similar to that of aspirin and clopidogrel which are commonly used at present, and can become an effective and safe therapeutic drug for cerebral arterial thrombosis.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a PSD-95 PDZ2 peptidomimetic inhibitor and application thereof. A series of compounds are designed and synthesized by taking a tetrapeptide ETAV as a template, a structure-activity relationship of the compounds with PSD-95 PDZ2 is systematically studied, and an optimal compound 32-2, i.e., the PSD-95 PDZ2 peptidomimetic inhibitor, is screened, a structural formula of which is shown as formula (I), the PSD-95 PDZ2 peptidomimetic inhibitor has very excellent plasma stability, and exhibits significant neuroprotective activity in in-vivo and in-vitro biological activity evaluation, significantly reduces cerebral infarction caused by cerebral ischemia-reperfusion injury, and can be used for preparing a drug for treating ischemic stroke. (I).

The invention belongs to the technical field of biological medicines, and particularly discloses a self-assembled nano preparation coated with a macrophage membrane as well as a preparation method and application of the self-assembled nano preparation. According to the nano preparation, nano particles formed by self-assembly of epigallocatechin gallate (EGCG), ferric chloride (FeCl3) and edaravone (EDV) serve as a core, and the outer layer of the nano preparation is coated with a macrophage membrane. The preparation method is a one-pot method and comprises the following steps: mixing and self-assembling EGCG, FeCl3 and EDV in a phosphate buffer solution, carrying out centrifugal purification, and carrying out ultrasonic fusion with a macrophage membrane. The nano preparation is uniform in particle size, has excellent free radical scavenging capacity and antioxidant activity, can effectively pass through a blood-brain barrier and target a cerebral ischemia reperfusion injury area, and shows a remarkable effect in preparation of drugs for treating cerebral arterial thrombosis.

The invention discloses a strain of lactobacillus acidophilus for treating chronic cerebral ischemia, which is preserved in the China Center for Type Culture Collection (CCTCC) and has the preservation number of CCTCC NO: M 20251505. Animal experiments show that the strain can reduce the death rate of chronic cerebral ischemia model mice and improve neurological impairment, motion coordination and spatial learning and memory ability of the chronic cerebral ischemia model mice. Mechanism research shows that the strain can increase histone acetylation and BDNF secretion by inhibiting the activity of astrocyte HDAC1, and meanwhile, can inhibit an NF-kappa B signal channel and reduce inflammatory factor release by activating a microglial cell GPR120 receptor, so that a neuroprotective effect is achieved through an'intestine-brain axis'. The invention provides a new candidate strain for the development of microbial preparations for preventing and / or treating chronic cerebral ischemia and related cognitive impairment.

The invention discloses application of a PLAU signal channel inhibitor in treating ischemic cerebral apoplexy and a pharmaceutical composition, and belongs to the field of biological medicine. The PLAU signal channel inhibitor inhibits the activation of an NF-kappa B channel and reduces the generation of inflammatory factors (IL-1beta, IL-6 and TNF-alpha) by inhibiting the expression of PLAU protein in cells. Experiments prove that the PLAU signal channel inhibitor can remarkably improve related pathological indexes of ischemic cerebral apoplexy, the cerebral infarction area is reduced by more than or equal to 30%, the vascular endothelial cell activity is improved by more than or equal to 25%, the inflammatory factor level is reduced by more than or equal to 40%, and the protective effect on cerebral ischemia reperfusion injury is superior to the overall effect of a traditional Chinese medicine compound. The invention provides a clear mechanism basis for targeted therapy of ischemic cerebral apoplexy.

The invention belongs to the technical field of cell culture, and discloses a cell culture device for an experiment for treating cerebral ischemia stroke based on long non-coding RNA, the cell culture device comprises an incubator, a cross-shaped partition plate is fixedly connected in the incubator, a culture mechanism is arranged in the incubator, the culture mechanism comprises four stabilizing assemblies and a temperature control assembly, and the temperature control assembly is connected with the cross-shaped partition plate. The stabilizing assembly and the temperature control assembly are matched for use, the stabilizing assembly comprises sliding rails, the sliding rails are fixedly connected to the interior of the incubator, and sliding blocks are symmetrically and slidably connected to the interiors of the two sliding rails. By arranging the culture mechanism, stable, independent and environment-controllable parallel culture is carried out on a plurality of experimental samples in the same culture box, the culture dish can be stably clamped and fixed to prevent accidental overturning, and the culture dish has the partitioned independent temperature control capability; therefore, stable, reliable and flexible hardware support is provided for related frontier biomedical research.

This invention relates to the field of biomedical technology, specifically to the application of OGR1 as a target in the preparation of drugs for treating cerebral ischemia. This invention utilizes a viral vector to overexpress OGR1 in neurons surrounding infarcts. Ogr1 Treatment with OGR1 agonists can significantly promote the recovery of motor function and nerve repair after cerebral ischemia, and the treatment time window is at least 3-7 days after cerebral ischemia, which significantly enhances the treatment effect of cerebral ischemia.

The present disclosure relates to compositions comprising N, N-dimethyltryptamine or a salt thereof and N, N-dimethyltryptamine or a salt thereof, pharmaceutical compositions comprising a combination of N, N-dimethyltryptamine or a salt thereof and N-acylethanolamine or a salt thereof with at least one pharmaceutically acceptable carrier and / or excipient and their use in a method of treating cerebral ischemia or hypoxia by administering the composition in a therapeutically effective amount to a subject in need thereof.

The invention discloses a salicylic acid compound as well as a pharmaceutical composition and application thereof. The salicylic acid derivative disclosed by the invention can be used for remarkably improving ischemia symptoms of cerebral ischemia reperfusion model rats, and has a wide application prospect in preparation of medicines for preventing and treating cardio-cerebral ischemic diseases, improving cardio-cerebral circulatory disorder, resisting thrombus and the like.

The invention discloses an effect of TMEM159 in preparation of a medicine for treating cerebral ischemia reperfusion injury. According to the application disclosed by the invention, molecular biology experiments find that the expression of the TMEM159 in cerebral ischemia reperfusion brain tissues is reduced, and single cell sequencing data in a public database shows that the TMEM159 is mainly expressed in neuronal cells; an AAV9-mediated nerve cell specific TMEM159 overexpression adeno-associated virus vector is further constructed to verify the application of TMEM159 as a treatment target, and the result shows that the TMEM159 overexpression can reduce the cerebral infarction area caused by cerebral ischemia and reduce the cell apoptosis level; therefore, the invention provides a new therapeutic target and medicine for the cerebral ischemia disease, and the TMEM159 overexpression adeno-associated virus provided by the invention has the advantages of long-term expression, low toxicity, low immunogenicity, high tissue specificity and the like, and has good application prospects and transformation values.

Disclosed are an aromatic alkylamine ferroptosis inhibitor based on a butylphthalide structure, a preparation method therefor, and an application thereof. The chemical structural formula of the ferroptosis inhibitor is as shown in formula (1) or formula (2). The ferroptosis inhibitor is capable of inhibiting ferroptosis caused by a ferroptosis inducer, and reduces the level of intracellular reactive oxygen species. The ferroptosis inhibitor reduces neurological damage caused by cerebral ischemia-reperfusion, and alleviates symptoms of neurological disorders such as Alzheimer's disease and Parkinson's disease. Compared to the ferroptosis inhibitor Ferrostatin-1, the arylalkylamine compound exhibits better metabolic stability and is suitable for in-vivo efficacy evaluation. Therefore, the novel arylalkylamine compound provided by the present invention demonstrates great application value in the treatment of ferroptosis-related neurological disorders.

The application belongs to the technical field of medicine, and particularly relates to a muscone derivative, a preparation method and application thereof. The muscone derivative cyclopentadecanedione monoxime has obvious advantages over muscone and other derivatives in improving the MCAO rat mNSS score, microcirculation blood flow, reducing the cerebral infarction rate, the cortical and hippocampal neuron necrosis rate, and the brain water content, and increasing the SOD and CAT contents of the rat brain tissue which are abnormally reduced due to ischemia, and is a potential effective drug for cerebral ischemia-reperfusion injury.

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

The present application relates to a kind of cytidine choline dextrohydrotalcid derivatives and its preparation method and application, belong to biological medicine technical field.The present application is aimed at solving the technical problems of low blood-brain barrier penetration rate and limited treatment effect of existing edaravone dextrohydrotalcid compound preparation.The present application prepares a dextrohydrotalcid derivative (C-B) with boronic acid structure, then it is compounded with cytidine choline in specific pH buffer system, and forms cytidine choline dextrohydrotalcid derivative (C-D-B).The present application can effectively improve the efficiency of drug crossing blood-brain barrier by using the dynamic covalent characteristics of boronic ester bond and free radical responsiveness.The experimental results show that, compared with existing combination drug, the derivative of the present application can significantly reduce the infarction area of cerebral ischemia model animal, reduce cell damage and active oxygen level, and promote vascular regeneration, and show better treatment effect on ischemic brain injury.